Proximity medicine discovery platform using a generalized effector protein discovery engine to develop programmable therapeutics.
General Proximity has built the first generalized, mechanism-agnostic proximity discovery platform that identifies effector proteins and molecular proximity mechanisms (the effectome) to enable control of target protein biology. The platform discovers new proximity-based medicines that can achieve diverse effects including protein degradation, re-localization, activation, and reprogramming, targeting previously undruggable proteins. The team has been responsible for 40+ FDA-approved medicines, 175+ INDs, and 270 patents. General Proximity is a product of General Proximity.